Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07344324

Study Evaluating the Safety and Feasibility of Endoscopic Duodenal Injections of Autologous Mesenchymal Stem Cells

Type 2 Diabetes Mellitus (T2DM) pathogenesis increasingly involves "diabetic duodenopathy," characterized by proximal intestinal immune and epithelial dysregulation. This study investigates the endoscopic delivery of adipose-derived mesenchymal stem cells (ADMSCs) into the duodenum and proximal jejunum as a disease-modifying therapy. By leveraging the paracrine immunomodulatory and regenerative effects of ADMSCs in close proximity to the pancreatico-enteroendocrine system, this targeted approach aims to restore insulin sensitivity and $\\beta$-cell function while minimizing systemic exposure. The clinical safety and feasibility of this novel delivery route remain to be established.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Diabete Type 2 Body Weight Diabetes Mellitus Diabetes Mellitus, Type 2 Endocrine System Diseases Glucose Metabolism Disorders Insulin Resistant Diabetes (Mellitus) Metabolic Diseases Nutrition Disorders Nutritional and Metabolic Diseases Obesity Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

25 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • • Adults aged between 25-70 years
  • Diagnosis of T2DM from at least 1 years
  • HbA1c between 7.5% and 10%
  • BMI between 25 and 35 kg/m²
  • Fasting C-peptide ≥1 ng/ml
  • Stable antidiabetic regimen for ≥3 months (including insulin s.c.)
  • Insulin resistance (HOMA-IR > 5)
  • Healthy volunteers: BMI < 25, age between 18-75 and no diagnosis of T2DM or insulin resistance (HOMA-IR<2.5), with no significant acute or chronic medical conditions and not taking medications that could interfere with the esophagogastroduodenoscopy + biopsies

Exclusion criteria

  • Type 1 DM or secondary diabetes
  • Celiac disease
  • History of pancreatitis or GI surgery
  • Active infection or malignancies ongoing
  • Active gastro-duodenal ulcers
  • Duodenum not accessible endoscopically for previous surgery or other conditions
  • History of autoimmune disease
  • Active malignancy or recent cancer treatment
  • Use of certain medications (e.g., immunosuppressants, systemic corticosteroids)
  • Active Smoking (>5 sigarettes/die)
  • Anticoagulant treatment not suspendable
  • Myocardial infarction during the past 6 months or/and heart failure class III or IV according to the New York Heart association's classification.
  • Drug or alcohol abuse
  • Continuous glucocorticoid or anti-inflammatory treatment
  • Uncontrolled thyroid disease.
  • Pregnancy, breastfeeding
  • Psychiatric or cooperative problems or low compliance that is a contraindication from participating in the study.
  • Liver cirrhosis of any Child-Phugh stage or MELD> 15
  • Chronic Severe Renal Insufficiency (eGFR < 30 ml/min/1.73 m2 based on CKD-EPI equation)
  • Currently participating in other study, or previously participated in an experimental drugs trial within 30 days before or 5 half-life of the drug administered
  • Any health issue that might put the patient at risk if the treatment is performed, judged by the investigator.

Treatment and study plan

endoscopic duodenal injection of ADMSCs

Procedure

Biopsy Protocol Mucosal biopsies (12 at baseline; 6 at follow-up) will be collected from the Treitz angle to the genu inferius. Samples for ex vivo analysis will be transported at 37°C in sterile medium within 15 minutes.

ADMSC Preparation and Delivery Autologous adipose tissue, harvested via mini-liposuction, will undergo mechanical activation (ELEA Method: 2000 rpm for 8 min). The activated fat is filtered (2 mm), emulsified, and loaded into a 19-gauge needle. Under deep sedation, the substrate will be injected submucosally from the Treitz angle to the superior duodenal genu, ensuring papilla preservation.

Primary outcomes

  1. Number of Participants With Treatment-Related Adverse Events as Assessed by Common Terminology Criteria for Adverse Events Version 5.0

    Time frame: From the time of the endoscopic procedure through Month 12 post-procedure.

    Assessment of the safety and tolerability of the endoscopic duodenal injection of autologous adipose tissue-derived Mesenchymal Stem Cells. Safety will be evaluated by monitoring the frequency and severity of all adverse events and serious adverse events occurring during the study period.

Secondary outcomes

  1. Change From Baseline in Glycated Hemoglobin at Month 12

    Time frame: Baseline (Day 0) and Month 12.

    Mean change from baseline in Glycated Hemoglobin (HbA1c) levels. This physiological parameter is used to evaluate the long-term control of blood sugar levels. The data will be aggregated as the mean change from the start of the study to the final follow-up.

  2. Change From Baseline in Total Daily Insulin Requirement at Month 12

    Time frame: Baseline (Day 0) and Month 12.

    Mean change from baseline in the total daily dose of insulin required by the participant. The dose is measured in International Units per Kilogram per Day. This measure assesses if the treatment reduces the patient's dependence on external insulin.

  3. Change From Baseline in Fasting C-peptide Levels at Month 12

    Time frame: Baseline (Day 0) and Month 12.

    Mean change from baseline in fasting C-peptide levels. This parameter is used as a surrogate marker for endogenous insulin production and pancreatic beta-cell function. It is measured in nanograms per milliliter.

  4. Change From Baseline in Lipid Profile Parameters at Month 12

    Time frame: Baseline (Day 0) and Month 12.

    Mean change from baseline in lipid profile parameters, including Total Cholesterol, Low-Density Lipoprotein (LDL), High-Density Lipoprotein (HDL), and Triglycerides. These physiological parameters are measured in milligrams per deciliter (mg/dL) to evaluate the metabolic impact of the Mesenchymal Stem Cell transplantation. Data will be aggregated as the mean change for each lipid component.

Study contacts

Contact information is provided by the study sponsor or research team.

IVO BOSKOSKI

CONTACT

[email protected]

+39 06 3015 6580

Sponsors and collaborators

Lead sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Other

Registry information

Official study title

A Pilot Study Evaluating the Safety, Feasibility, and Therapeutic Potential of Endoscopic Duodenal Injection of Adipose Tissue-Derived Mesenchymal Stem Cells in Patients With Type 2 Diabetes Mellitus.

Acronym: STEM-DM

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jan 15, 2026
Registry last updated
Jan 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.